Radioligand therapy has been around for a long time, but 2025 was the year it started to look less like a niche tool and more like something oncology teams have to actively plan for. In March 2025, ...

Celebrate International Day of Women and Girls in Science 2026 by discovering some of the most influential women shaping biotech today.

Delve into the Astellas playbook, a strategy relying on "strategic brand" and advancing on "primary focuses" at the same time ...

Sustained interest in small molecules, bispecific antibodies, and genomics got the ball rolling in the biotech deals arena in ...

The companies Aktis Oncology, Alumis, and Parabilis Medicines bagged the biggest biotech funding rounds overall in January ...

Delve into the Amarin v. Hikma case in which the U.S. Supreme Court might settle the skinny label question once and for all.

Discover how AI is transforming biologics discovery, tackling adoption challenges, and driving growth in the biologics market.

As 2025 comes to an end, it’s a good moment to take a look at what happened this year in biotech. Unlike years defined by one big breakthrough, 2025 felt more like a phase shift, where many trends ...

For this year’s ‘biotechs to watch’ selection, each Labiotech journalist picked five companies they believe will be worth following in 2026. Some earned their spot after clear momentum in 2025, while ...

In one of the standout deals of the year so far, Roche entered into a $5.3 billion collaboration and license agreement with peptide therapeutics company Zealand Pharma to co-develop and ...

The need for change in Novo Nordisk’s operations became irrefutably clear in July, when the company named its new CEO, Maziar Mike Doustdar, and simultaneously issued a profit warning for its ...